Research revealed that anti-HER2 monoclonal antibody (mAb) are unable to kill tumor cells when not bound to FcR, and patients treated with trastuzumab showed an increase in FcR+ cell infiltration (Arnould et al., 2006; Varchetta et al., 2007). This evidence concerns the gene ERBB2 and neoplasm.